Table 3.
Chemotherapy received in patients from Study 1 and Study 2—safety population (cycle 1)
| Study 1 chemotherapya, % | NEPA (N = 725) | PALO (N = 725) | Overall (N = 1450) |
|---|---|---|---|
| ACb | |||
| Doxorubicin | 68.0 | 63.6 | 65.8 |
| Cyclophosphamide | 99.9 | 99.9 | 99.9 |
| Epirubicin | 32.0 | 36.3 | 34.2 |
| Study 2 chemotherapya, % | NEPA (N = 308) | APR‐PALO (N = 104) | Overall (N = 412) |
|---|---|---|---|
| MECc | 75.7 | 75.7 | 75.7 |
| Carboplatin | 60.3 | 61.5 | 60.6 |
| Oxaliplatin | 20.1 | 24.4 | 21.2 |
| Doxorubicind | 11.1 | 6.4 | 9.9 |
| Cyclophosphamided | 3.4 | 2.6 | 3.2 |
| Irinotecan | 3.0 | 3.8 | 3.2 |
| Epirubicind | 1.7 | 1.3 | 1.6 |
| Daunorubicin | 0.4 | 0 | 0.3 |
| HECc | 24.3 | 24.3 | 24.3 |
| Cisplatin | 96.0 | 92.0 | 95.0 |
| Dacarbazine | 4.0 | 4.0 | 4.0 |
| Carmustine | 0 | 4.0 | 1.0 |
AC, anthracycline‐cyclophosphamide; APR, aprepitant; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; NEPA, netupitant‐palonosetron, PALO: palonosetron.
a
Percentages are based on efficacy (full analysis) population, while all others are based on safety population (cycle 1).
b
Breast cancer patients scheduled to receive AC‐based chemotherapy in Study 2 were not eligible.
c
Cycle 1 chemotherapy.
d
Cyclophosphamide and doxorubicin or epirubicin were administered together as “AC” in Study 1.